StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Wedbush Stays Sidelined on bluebird bio (BLUE) But Does Sees 'some short-term benefits' for the Company Following Skysona News
September 19, 2022 9:28 AM
Wedbush analyst David Nierengarten reiterated a Neutral rating and $9.00 price target on bluebird bio (NASDAQ: BLUE).The analyst comments "While ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
Hot Comments
Next Articles
Pre-Open Movers: Wix Gains on Activist Stake, Take-Two Falls on GTA6 Hack
September 19, 2022 9:19 AM
Form 8-K bluebird bio, Inc. For: Sep 16
September 19, 2022 7:06 AM
bluebird bio (BLUE) Granted FDA Accelerated Approval for SKYSONA
September 19, 2022 5:58 AM
bluebird bio Receives FDA Accelerated Approval for SKYSONA® Gene Therapy for Early, Active Cerebral Adrenoleukodystrophy (CALD)
September 16, 2022 11:51 PM
